HR Price Prediction Next Week
Analysis and Insights
To predict the stock price of Healthcare Realty Trust (HR) for the next trading week, we analyze both news sentiment and technical indicators.
News Sentiment Analysis:
- Scotiabank lowered the price target for HR from $18 to $17, maintaining a Sector Perform rating, citing fiscal 2025 FFO guidance that slightly missed expectations due to higher joint venture contributions and bad debt expenses from tenant bankruptcies.
- Despite challenges, Q4 fiscal 2024 showed positive multi-tenant absorption results, aligning with management's expectations and indicating potential growth in same-store cash NOI for FY25.
- Analyst ratings are mixed, with Wedbush downgrading HR to Underperform with a $16 price target, while Wells Fargo maintains an Underweight rating with a $17 target.
Technical Analysis:
- Current price: $17.005
- RSI (14): 51.79, indicating a neutral position
- MACD: Slightly bullish crossover
- Fibonacci resistance levels: $17.11 (R1) and $17.34 (R2)
- Fibonacci support levels: $16.40 (S1) and $16.18 (S2)
Price Prediction:
Based on the analysis, HR is expected to trade between $16.40 and $17.11 next week. The stock is likely to face resistance at $17.11, and without strong bullish momentum, it may consolidate or slightly decline.
Recommendation:
Sell at the current price of $17.005, as the stock is approaching resistance levels and lacks strong upward momentum. Consider re-entering if the price dips below $16.40.
HR Similar Chart Price Prediction
The price of HR is predicted to go up 9.34%, based on the high correlation periods with BNL. The similarity of these two price pattern on the periods is 90.43%.
HR
BNL
Up: 9.34%Similarity: 90.43%
HR Revenue Forecast
HR EPS Forecast
HR FAQs
What is HR revenue forecast for next quarter？
HR Analyst's Forecast
Richard Anderson
Wedbush
Hold → Sell
2025-01-02
Price Target
$18 → $16
Downside
-2.85%
Wedbush downgraded Healthcare Realty Trust to Underperform from Neutral with a price target of $16, down from $18. The company "remains a work in progress" but the stock's trades at a 2-to-3 turn multiple premium to its nearest peer, the analyst tells investors in a research note. The firm says Healthcare Realty resetting leadership may "expend energy that could otherwise be directed toward growing the business."
Michael Mueller
JP Morgan
Buy → Hold
2024-12-20
Price Target
$19
Upside
+12.56%
Joseph Feldman
Wells Fargo
Sell
2024-10-01
Price Target
$16 → $17
Downside
-5.03%
